z-logo
open-access-imgOpen Access
Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars
Author(s) -
Sarfaraz K. Niazi
Publication year - 2022
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s378813
Subject(s) - biosimilar , medicine , clinical trial , clinical pharmacology , clinical efficacy , mindset , risk analysis (engineering) , pharmacology , intensive care medicine , computer science , artificial intelligence

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here